Waterfront Wealth Inc. Has $1.06 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Waterfront Wealth Inc. grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,633 shares of the specialty pharmaceutical company’s stock after buying an additional 103 shares during the quarter. Waterfront Wealth Inc.’s holdings in Jazz Pharmaceuticals were worth $1,062,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in JAZZ. Covestor Ltd grew its position in Jazz Pharmaceuticals by 676.5% during the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after acquiring an additional 345 shares during the last quarter. Spire Wealth Management increased its holdings in Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 238 shares in the last quarter. Headinvest LLC bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth about $56,000. Signaturefd LLC increased its holdings in Jazz Pharmaceuticals by 85.7% during the 3rd quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 252 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $78,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Philip L. Johnson acquired 12,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ traded down $1.80 during trading hours on Wednesday, hitting $107.10. The stock had a trading volume of 592,713 shares, compared to its average volume of 614,110. Jazz Pharmaceuticals plc has a one year low of $106.61 and a one year high of $146.70. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The firm has a market capitalization of $6.75 billion, a price-to-earnings ratio of 17.50, a P/E/G ratio of 1.53 and a beta of 0.59. The company has a 50 day simple moving average of $120.35 and a two-hundred day simple moving average of $122.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. Research analysts forecast that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on JAZZ shares. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. Piper Sandler raised their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Truist Financial reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. HC Wainwright cut their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.